NASDAQ:CDTX
Cidara Therapeutics Stock News
$0.92
+0.0779 (+9.25%)
At Close: Mar 28, 2024
Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates
09:35pm, Wednesday, 11'th May 2022 Zacks Investment Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
08:13pm, Wednesday, 11'th May 2022 GlobeNewswire Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patient
Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates
06:49pm, Wednesday, 11'th May 2022
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
09:25pm, Tuesday, 10'th May 2022 Zacks Investment Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -2.08% and 7.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO and CAMBRIDGE, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced that the companies will present new clinical data a
Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza
12:00pm, Thursday, 31'st Mar 2022 GlobeNewswire Inc.
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform and is designed to transform the standard of care for seasonal influenza prevention
Cidara Therapeutics (CDTX) Reports Q4 Loss, Tops Revenue Estimates
11:55pm, Monday, 07'th Mar 2022 Zacks Investment Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 21.21% and 84.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
10:41pm, Monday, 07'th Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patie
Cidara Therapeutics (CDTX) Reports Q4 Loss, Tops Revenue Estimates
08:16pm, Monday, 07'th Mar 2022
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 21.21% and 84.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cidara/Mundipharma rezafungin gets promising innovative medicine status in UK
01:02pm, Thursday, 03'rd Mar 2022 Seeking Alpha
Mundipharma and Cidara Therapeutics (CDTX) said that the Medicines and Healthcare Products Regulatory Agency ((MHRA)) in the U.K. granted rezafungin Promising Innovative Medicine…
Will Cidara Therapeutics (CDTX) Report Negative Q4 Earnings? What You Should Know
08:02pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Clears Cidara Therapeutics'' Phase 1 Trial For Immunotherapeutic Antiviral For Influenza
03:12pm, Monday, 14'th Feb 2022 Benzinga
The FDA has signed off Cidara Therapeutics Inc'' s (NASDAQ: CDTX ) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 for influenza. CD388 is a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza, added the Company. Cidara Full story available on Benzinga.com
Cidara announces FDA acceptance of its request to study the flu candidate
01:31pm, Monday, 14'th Feb 2022 Seeking Alpha
Cidara Therapeutics (CDTX) is trading ~3% higher in the pre-market on Monday after the company announced that the FDA accepted its Investigational New Drug ((IND)) application for the…
Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza
01:00pm, Monday, 14'th Feb 2022 GlobeNewswire Inc.
Cidara intends to initiate the Phase 1 trial in Q1 2022
FDA Clears Cidara Therapeutics' Phase 1 Trial For Immunotherapeutic Antiviral For Influenza
10:12am, Monday, 14'th Feb 2022
The FDA has signed off Cidara Therapeutics Inc's (NASDAQ: CDTX) Investigational New Drug (IND) application for its lead flu drug-Fc conjugate (DFC), CD388 for influenza. CD388 is a highly potent, lo